Feedback
Dehydroepiandrosterone, Serum or Plasma
2001640
Ordering Recommendation

Adjunct test for the investigation of hyperandrogenic and adrenal disorders. Not recommended for initial evaluation of polycystic ovarian syndrome.

Mnemonic
DHEA TMS
Methodology
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
Collect between 6-10 a.m. 
Collect
Serum separator tube or green (sodium or lithium heparin). Also acceptable: Lavender (EDTA). 
Specimen Preparation
Separate serum or plasma from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.3 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
 
Remarks
 
Stability
After separation from cells: Ambient: 24 hours; Refrigerated: 1 week; Frozen: 6 months 
Reference Interval
Effective August 19, 2013
AgeFemaleMale
PrematureLess than 40 ng/mLLess than 40 ng/mL
0-1 dayLess than 11 ng/mLLess than 11 ng/mL
2-6 daysLess than 8.7 ng/mLLess than 8.7 ng/mL
7 days-1 monthLess than 5.8 ng/mLLess than 5.8 ng/mL
1-5 monthsLess than 2.9 ng/mLLess than 2.9 ng/mL
6-24 monthsLess than 1.9 9 ng/mLLess than 2.5 ng/mL
2-3 yearsLess than 0.85 ng/mLLess than 0.63 ng/mL
4-5 yearsLess than 1.03 ng/mLLess than 0.95 ng/mL
6-7 yearsLess than 1.79 ng/mL0.06-1.93 ng/mL
8-9 years0.14-2.35 ng/mL0.10-2.08 ng/mL
10-11 years0.43-3.78 ng/mL0.32-3.08 ng/mL
12-13 years0.89-6.21 ng/mL0.57-4.10 ng/mL
14-15 years1.22-7.01 ng/mL0.93-6.04 ng/mL
16-17 years1.42-9.00 ng/mL1.17-6.52 ng/mL
18-39 years1.33-7.78 ng/mL1.33-7.78 ng/mL
40 years and older0.63-4.70 ng/mL0.63-4.70 ng/mL
Postmenopausal0.60-5.73 ng/mLDoes Not Apply
Tanner Stage I0.14-2.76 ng/mL0.11-2.37 ng/mL
Tanner Stage II0.83-4.87 ng/mL0.37-3.66 ng/mL
Tanner Stage III1.08-7.56 ng/mL0.75-5.24 ng/mL
Tanner Stage IV-V1.24-7.88 ng/mL1.22-6.73 ng/mL

Interpretive Data


Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
CPT Code(s)
82626
Components
Component Test Code*Component Chart NameLOINC
2001641Dehydroepiandrosterone by TMS2193-1
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • DHEA (Dehydroepiandrosterone, Serum or Plasma)
  • Unconjugated DHEA (Dehydroepiandrosterone, Serum or Plasma)